Search

Displaying results 4731 - 4740 of 7063 in total
  1. Drug

    RTA 744

    go.drugbank.com/drugs/DB05920
    Investigational

    Anthracyclines are one of the most broadly used and effective classes of cancer therapies; however, they are not used to treat brain cancers because current therapies do not cross the blood-brain barrier … RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers.

  2. Drug

    Thymectacin

    go.drugbank.com/drugs/DB05116
    Investigational

    Thymectacin is selectively active against tumor cells expressing high levels of thymidylate synthase (TS), a critical enzyme in DNA biosynthesis. … Thymectacin, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel small molecule anticancer agent.

  3. Drug

    PRO 2000

    go.drugbank.com/drugs/DB05385
    Investigational

    PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials.

    Categories: Compounds used in a research, industrial, or household settingInternational brands: Lavelin FA
  4. Drug

    TA-NIC

    go.drugbank.com/drugs/DB05445
    Investigational

    TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients.

    Synonyms: TA-NIC
  5. Drug

    EW-A-401

    go.drugbank.com/drugs/DB05525
    Investigational

    EW-A-401 is a circle of genetic material (plasmid DNA) that instructs the body to produce a genetically-engineered transcription factor, a protein that regulates expression of genes. … This specific transcription factor has been shown in animal studies to increase expression of the VEGF-A gene, and to promote the growth of new blood vessels.

    Synonyms: EW-A-401 DNA Plasmid Vector
  6. Drug

    VB10.16

    go.drugbank.com/drugs/DB17512
    Investigational

    VB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers. … It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting

  7. Drug

    Binodenoson

    go.drugbank.com/drugs/DB04853
    Investigational

    Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor. … This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion

  8. Drug

    L523S

    go.drugbank.com/drugs/DB06498
    Investigational

    [A175909] It has been investigated as a lung cancer vaccine. … antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) and when delivered following incorporation into an E1B-deleted adenovirus (Ad

  9. Drug

    Oxytocin

    go.drugbank.com/drugs/DB00107
    ApprovedInvestigationalVet approved

    [A229008,A228593] In the mid-1950s, synthetic oxytocin was successfully synthesized by a biochemist named Vincent du Vigneaud; he was later recognized with a Nobel prize for his work. … [A229013] Oxytocin also serves a role in metabolic homeostasis and cardiovascular regulation.[A228593,A229098]

  10. Drug

    Voclosporin

    go.drugbank.com/drugs/DB11693
    ApprovedInvestigational

    [L31218] This [cyclosporine] A analog was approved by the FDA on January 22, 2021 following promising results in clinical trials. … LN is a significant cause of renal failure, morbidity, and death in patients with SLE.